Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146023 | 0.80 | MAPK14 (0.39) | CYP1A2CYP2C9CYP2C19CA2MAPK14 | |
| SCHEMBL7758951 | 0.77 | MAPT (0.45) | CYP1A2CA2MAPTMEN1POLB | |
| SCHEMBL13672064 | 0.74 | MAPT (0.39) | CA2MAPTMEN1POLBKMT2A | |
| SCHEMBL15244283 | 0.74 | DRD4 (0.42) | CA2MAPK14MAPTMEN1KMT2A | |
| SCHEMBL21838982 | 0.73 | GPR35 (0.40) | CA2MAPK14ALDH1A1 | |
| SCHEMBL21838980 | 0.73 | GPR35 (0.40) | CA2MAPK14ALDH1A1 | |
| SCHEMBL13581453 | 0.73 | MAPT (0.49) | MAPK14MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL5473672 | 0.73 | MAPT (0.49) | MAPK14MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL12518685 | 0.72 | DRD4 (0.45) | CYP1A2CYP2C9CYP2C19CA2MAPT | |
| SCHEMBL15244041 | 0.72 | S1PR4 (0.48) | CA2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1195522-C | Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist | HOFFMANN LA ROCHE (CH) | 2005-04-06 | — | — | CN | disclosed |
| EP-1224174-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | EP | disclosed |
| CN-1379765-A | Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| EP-1224174-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2001029011-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |